Orbimed Advisors Llc Buys AbCellera Biologics Inc, Kinnate Biopharma Inc, UnitedHealth Group Inc, Sells Alexion Pharmaceuticals Inc, Acceleron Pharma Inc, Ascendis Pharma A/S

• New Purchases: ABCL, KNTE, UNH, PFE, ANTM, GLTO, MREO, MOH, OLMA, PAND, KDNY, SYRS, PCVX, IMGN, VTGN, PRAX, VTRS, NBTX, LUNG, TCRR, STRO, COGT, FDMT, MASS, PPBT,
• Added Positions: XTNT, BSX, GH, ABBV, CNC, ARQT, VRTX, APTO, NSTG, EW, ARCT, CRIS, TRIL, DXCM, LOGC, MIST, EHTH, ADVM, ACAD, FLXN, MGTX, OSH, MRK, APLT, FLDM, SNDX, HUM,
• Reduced Positions: ALXN, ASND, BIIB, MRTX, PRTA, BNR, CRSP, FBRX, MRSN, ALPN, ALEC, EPIX, SELB, ATNX, ACHC, BLU, ZYME, IFRX,
• Sold Out: XLRN, EXEL, NVO, ISEE, ALBO, CLDX, RCKT, MYOV, ARNA, OBSV, KYMR, ANAB, NBRV, 1YI1, RNA, CALT, BLRX,

For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/orbimed+advisors+llc/current-portfolio/portfolio

1. Prelude Therapeutics Inc (PRLD) - 15,594,877 shares, 10.36% of the total portfolio.
2. SpringWorks Therapeutics Inc (SWTX) - 7,406,307 shares, 4.99% of the total portfolio.
3. PMV Pharmaceuticals Inc (PMVP) - 7,330,423 shares, 4.19% of the total portfolio.
4. AbCellera Biologics Inc (ABCL) - 8,400,768 shares, 3.14% of the total portfolio. New Position
5. Turning Point Therapeutics Inc (TPTX) - 2,745,327 shares, 3.11% of the total portfolio.

Orbimed Advisors Llc initiated holding in AbCellera Biologics Inc. The purchase prices were between $39 and $58.9, with an estimated average price of $45.73. The stock is now traded at around $24.750000. The impact to a portfolio due to this purchase was 3.14%. The holding were 8,400,768 shares as of 2020-12-31.

Orbimed Advisors Llc initiated holding in Kinnate Biopharma Inc. The purchase prices were between $36.35 and $45.25, with an estimated average price of $40.13. The stock is now traded at around $29.030000. The impact to a portfolio due to this purchase was 1.42%. The holding were 3,847,929 shares as of 2020-12-31.

Orbimed Advisors Llc initiated holding in UnitedHealth Group Inc. The purchase prices were between $303.68 and $356.82, with an estimated average price of $335.55. The stock is now traded at around $376.480000. The impact to a portfolio due to this purchase was 1.27%. The holding were 390,300 shares as of 2020-12-31.

Orbimed Advisors Llc initiated holding in Pfizer Inc. The purchase prices were between $33.42 and $42.56, with an estimated average price of $36.69. The stock is now traded at around $36.250000. The impact to a portfolio due to this purchase was 1.24%. The holding were 3,616,600 shares as of 2020-12-31.

Orbimed Advisors Llc initiated holding in Anthem Inc. The purchase prices were between $272.8 and $333.15, with an estimated average price of $307.47. The stock is now traded at around $371.310000. The impact to a portfolio due to this purchase was 0.93%. The holding were 310,500 shares as of 2020-12-31.

Orbimed Advisors Llc initiated holding in Galecto Inc. The purchase prices were between $12.51 and $16.84, with an estimated average price of $14.88. The stock is now traded at around $6.230000. The impact to a portfolio due to this purchase was 0.48%. The holding were 4,090,937 shares as of 2020-12-31.

Orbimed Advisors Llc added to a holding in Xtant Medical Holdings Inc by 687.17%. The purchase prices were between $1.11 and $1.62, with an estimated average price of $1.29. The stock is now traded at around $2.460000. The impact to a portfolio due to this purchase was 0.71%. The holding were 72,803,072 shares as of 2020-12-31.

Orbimed Advisors Llc added to a holding in Boston Scientific Corp by 34.57%. The purchase prices were between $33.15 and $41.97, with an estimated average price of $36. The stock is now traded at around $38.220000. The impact to a portfolio due to this purchase was 0.56%. The holding were 6,523,000 shares as of 2020-12-31.

Orbimed Advisors Llc added to a holding in Guardant Health Inc by 248.80%. The purchase prices were between $99.96 and $135.93, with an estimated average price of $115.17. The stock is now traded at around $135.570000. The impact to a portfolio due to this purchase was 0.46%. The holding were 538,200 shares as of 2020-12-31.

Orbimed Advisors Llc added to a holding in AbbVie Inc by 85.84%. The purchase prices were between $80.49 and $108.67, with an estimated average price of $96.24. The stock is now traded at around $105.980000. The impact to a portfolio due to this purchase was 0.4%. The holding were 862,300 shares as of 2020-12-31.

Orbimed Advisors Llc added to a holding in Vertex Pharmaceuticals Inc by 25.22%. The purchase prices were between $207.01 and $276.09, with an estimated average price of $228.74. The stock is now traded at around $214.640000. The impact to a portfolio due to this purchase was 0.37%. The holding were 834,100 shares as of 2020-12-31.

Orbimed Advisors Llc added to a holding in Arcutis Biotherapeutics Inc by 29.95%. The purchase prices were between $17.82 and $31.73, with an estimated average price of $24.44. The stock is now traded at around $28.130000. The impact to a portfolio due to this purchase was 0.37%. The holding were 6,073,850 shares as of 2020-12-31.

Orbimed Advisors Llc sold out a holding in Acceleron Pharma Inc. The sale prices were between $102.36 and $134.95, with an estimated average price of $117.3.

Orbimed Advisors Llc sold out a holding in Exelixis Inc. The sale prices were between $18.39 and $24.8, with an estimated average price of $20.88.

Orbimed Advisors Llc sold out a holding in Novo Nordisk A/S. The sale prices were between $63.89 and $73.8, with an estimated average price of $69.12.

Orbimed Advisors Llc sold out a holding in IVERIC bio Inc. The sale prices were between $5.65 and $7.66, with an estimated average price of $6.41.

Orbimed Advisors Llc sold out a holding in Albireo Pharma Inc. The sale prices were between $31.56 and $42.16, with an estimated average price of $36.4.

Orbimed Advisors Llc sold out a holding in Celldex Therapeutics Inc. The sale prices were between $14.99 and $22.75, with an estimated average price of $18.05.

Orbimed Advisors Llc reduced to a holding in Alexion Pharmaceuticals Inc by 92.26%. The sale prices were between $111.55 and $158.03, with an estimated average price of $128.71. The stock is now traded at around $154.875000. The impact to a portfolio due to this sale was -2.98%. Orbimed Advisors Llc still held 169,000 shares as of 2020-12-31.

Orbimed Advisors Llc reduced to a holding in Ascendis Pharma A/S by 54.19%. The sale prices were between $151.2 and $182.76, with an estimated average price of $165.51. The stock is now traded at around $130.810000. The impact to a portfolio due to this sale was -0.79%. Orbimed Advisors Llc still held 336,500 shares as of 2020-12-31.

Orbimed Advisors Llc reduced to a holding in Biogen Inc by 26.05%. The sale prices were between $236.26 and $355.63, with an estimated average price of $258.66. The stock is now traded at around $276.630000. The impact to a portfolio due to this sale was -0.68%. Orbimed Advisors Llc still held 529,400 shares as of 2020-12-31.

Orbimed Advisors Llc reduced to a holding in Prothena Corp PLC by 49.29%. The sale prices were between $10.12 and $13.94, with an estimated average price of $11.85. The stock is now traded at around $26.900000. The impact to a portfolio due to this sale was -0.23%. Orbimed Advisors Llc still held 1,797,458 shares as of 2020-12-31.

Orbimed Advisors Llc reduced to a holding in CRISPR Therapeutics AG by 28.29%. The sale prices were between $79.67 and $173.23, with an estimated average price of $118.75. The stock is now traded at around $111.240000. The impact to a portfolio due to this sale was -0.19%. Orbimed Advisors Llc still held 451,800 shares as of 2020-12-31.

Orbimed Advisors Llc reduced to a holding in Forte Biosciences Inc by 72.92%. The sale prices were between $28.66 and $46.79, with an estimated average price of $37.5. The stock is now traded at around $30.020000. The impact to a portfolio due to this sale was -0.15%. Orbimed Advisors Llc still held 92,200 shares as of 2020-12-31.